Category Archives: Cf

WeeklyHub

Today Analysts Focus on CF Industries Holdings, Inc. (CF), CenturyLink, Inc. (CTL) StockNewsJournal CF Industries Holdings, Inc. (CF) have shown a high EPS growth of -17.80% in the last 5 years and has earnings decline of -140.10% yoy. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, hold within the 3 ... Valuing 2 Stocks Using Ratios and Multiples: CenturyLink, Inc. (CTL ...AllStockNews all 44 news articles »

See more here:

Today Analysts Focus on CF Industries Holdings, Inc. (CF), CenturyLink, Inc. (CTL) - StockNewsJournal

Anthera Pharmaceuticalshas received news that could help it accelerate patient enrollment in aPhase 3 clinical trial ofSollpura (liprotamase)as a treatment for a digestive disorder known as cystic fibrosis-triggered exocrine pancreatic insufficiency.

The news is that a key Cystic Fibrosis Foundation committee approved the companys trial design. The sign-off from the foundationsTherapeutics Development NetworkProtocol Review Committee could lead to additional medical facilities taking part in the trial. And more facilities could mean stepped-up patient recruitment.

Depending on the speed of patient enrollment, results of the study are expected by years end or in early 2018, the company said.

Exocrine pancreatic insufficiency, a common feature of CF, makes it more difficult for a person to digest food. It stems from the thick mucus associated with cystic fibrosis blocking the discharge of enzymes the pancreas creates to facilitate digestion.

Sollpura isa pancreatic enzyme replacement therapy, or PERT. It contains the enzymes lipase, protease and amylase in the same concentrations that are found inthe stomach.

Most PERTs are derived from pigs. Sollupura isnot, which means it overcomes risks associated with obtaining enzymes from the animals. Those risks include viral contamination and limited supply.

The Phase 3 RESULT clinical trial (NCT03051490) that Anthera has just started will build on results of the Phase 3 SOLUTION trial (NCT02279498). SOLUTION demonstrated that Sollpura was as effectiveat treatingexocrine pancreatic insufficiency asPancreaze (pancrelipase), a pig-derived PERT.

A key finding of the SOLUTION trial was that both Sollpura and Pancreaze maintained patients height and weight, an indication their bodies were getting enough nutrients.

TheRESULT trial will further assess Sollpura capsules ability to overcome CF patientsexocrine pancreatic insufficiency, compared with Pancreaze. Researchers will adjust doses individually to try to achieve the best results.

We are very pleased to leverage the CFF TDN [Cystic Fibrosis Foundation] clinical trial network and are excited by the progress made with the implementation of the RESULT study, William Shanahan, chief medical officer of Anthera Pharmaceuticals, said in a press release.

Researchers are hoping to enroll 150 adults and children for the RESULT trialin the United States, Europe and Israel.

For more information about the trial and how to participate, please visit this link. Or you cancontact Monica Gangal by calling 1-510-856-5600 in the United States or email her atmgangal@anthera.com.

Read more here:

Cystic Fibrosis Foundation Opens Door to Anthera Speeding Up Trial of Digestive Disorder Therapy - Cystic Fibrosis News Today

APhase 3 studyof Sollpura (liprotamase), anon-porcine enzyme replacement therapy aiming to treatexocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) better than existing porcine-derived therapies, is now recruiting about 150 pediatricand adultpatientsin the United States, Europe and Israel.

Specifically, theexpandedtrialwillevaluate the efficacy or non-inferiority of Sollpura compared to pig-derived and enteric-coated pancreatic enzyme replacement therapies (PERTs) approved for CF patients with EPI, a condition caused by low enzyme levels in the digestive tract.Topline resultsare expected toward the end of 2017 or in early 2018.

As a PERT, Sollpura is beingdeveloped by Anthera to overcome nutrient malabsorption in CF patients due tochronic pancreatic inflammation and the thick mucus that blocks the discharge of pancreatic enzymes needed for digestion. It containsthe enzymes lipase, protease and amylase in a specific ratio designed to promote a healthy digestion of food. Because it is of non-porcine origin,Sollpuras therapeutic value should come without the risks associated withsimilar porcine-based drugs.

We are very much looking forward to supporting Anthera in their efforts to bring this novel, biotech-derived pancreatic enzyme replacement therapy to patients, Fernando Casals Seoane, MD, PhD, gastroenterology and hepatology specialist at Hospital Universitario de La Princesa, Madrid, said in a companypress release.

In a previous Phase 3 clinical study, calledSOLUTION (NCT02279498), researchers demonstrated the non-inferiority of Sollpura compared to Pancreaze, aporcine-derived PERT. The new clinical trial, RESULT (NCT03051490), will further assess the efficacy and safety of Sollpura capsules in comparison to thisPERT in CF patients with EPI, adjusting for dose frequency and levels as needed by an individual.

We have been involved with the Sollpura program since Anthera initiated its clinical development with the SOLUTION study and we are pleased that the RESULT study is now underway in Europe, said Amparo Sol Jover, MD, PhD, pulmonologist at Hospital La Fe de Valencia, also inSpain, and president of the Sociedad Espaola de Fibrosis Qustica.

The trial is expected to enroll about 150 patients, ages 7 and above, on a stable porcine PERT regime with well-controlled EPI, as measured by the coefficient of fat absorption (CFA). Participants will be randomized to receive either Sollpura or Pancreaze for four weeks. During the initial three weeks, researchers will conduct dose adjustments based on a patients symptoms and clinical evaluation to achieve the best therapeutic benefit.

Its primary endpoint, or objective, istreatment efficacy as seen in changes in CFA levels from baseline after four weeks of treatment. Those patients givenSollpura will be followed for an additional 20 weeks to evaluate long-term safety and efficacy.

Anthera also announced that the RESULT study was approved by theProtocol Review Committee of theCystic Fibrosis Foundations Therapeutics Development Network, which may bring further testing sites to this Phase 3 trial and aid in patient recruitment within the U.S.

Sollpura was also evaluated as a drinkable formulation (a powder for oral solution) in the Phase 3 SIMPLICITY clinical trial (NCT02734810). This power formulation mayprovide a more easy-to-administer source of PERT for pediatric patients and for those who receive their nutrition through feeding tubes.

For more information about the trial and how to participate, please visit this link.

Read more:

Phase 3 Study of Sollpura, Enzyme Replacement Therapy for CF Patients with EPI, Recruiting in Europe and US - Cystic Fibrosis News Today

Barron's

The Hot Stock: CF Industries Gains 6.6% Barron's CF Industries (CF) rose to the top of the S&P 500 today, helped by overall bullishness in the fertilizer sector. Illustration: Pixabay. CF Industries climbed $1.83 cents, or 6.6%, to $29.72, while the S&P 500 gained 2.25 point,s or 0.09%, to 2427.43 ...

Continued here:

The Hot Stock: CF Industries Gains 6.6% - Barron's

Iowa casinos revenue for FY 2017

Casino fiscal 2016 fiscal 2017

Ameristar/Council Bluffs

Adjusted Gross Revenue $168,960,868 $171,435,126

Admissions 1,896,714 1,856,303

Win Per Capita $89 $92

Casino Queen/Marquette (formerly Lady Luck)

Adjusted Gross Revenue $27,124,696 $26,384,268

Admissions 272,140 253,122

Win Per Capita $100 $104

Catfish Bend/Burlington

Adjusted Gross Revenue $43,838,051 $41,715,532

Admissions 756,663 668,883

Win Per Capita $58 $62

Diamond Jo/Dubuque

Adjusted Gross Revenue $67,561,683 $66,856,145

Admissions 977,925 917,395

Win Per Capita $69 $73

Diamond Jo Worth/Northwood

Adjusted Gross Revenue $86,539,765 $85,196,088

Admissions 1,266,893 1,237,613

Win Per Capita $68 $69

Grand Falls Casino Resort/Larchwood

Adjusted Gross Revenue $55,748,970 $54,802,316

Admissions 1,060,218 1,022,442

Win Per Capita $53 $54

Hard Rock/Sioux City

Adjusted Gross Revenue $83,178,970 $77,027,496

Admissions 1,958,105 1,721,017

Win Per Capita $42 $45

Harrahs Council Bluffs Casino & Hotel

Adjusted Gross Revenue $70,588,823 $71,271,483

Admissions 1,074,207 1,139,940

Win Per Capita $66 $63

Horseshoe Casino Council Bluffs

Adjusted Gross Revenue $175,623,055 $172,142,344

Admissions 1,996,594 2,016,310

Win Per Capita $88 $85

Isle of Capri/Bettendorf

Adjusted Gross Revenue $69,716,577 $77,459,196

Admissions 822,639 1,075,519

Win Per Capita $85 $72

Isle Casino Hote/Waterloo

Adjusted Gross Revenue $89,583,537 $87,034,926

Admissions 1,232,766 1,119,847

Win Per Capita $73 $78

Lakeside Casion/Osceola

Adjusted Gross Revenue $49,414,050 $48,135,113

Admissions 630,199 539,892

Win Per Capita $78 $89

Prairie Meadows Racetrack & Casino/Altoona

Adjusted Gross Revenue $182,515,752 $190,172,316

Admissions 2,926,388 3,155,137

Win Per Capita $62 $60

Q Casino/Dubuque (formerly Mystique)

Adjusted Gross Revenue $48,811,457 $47,639,628

Admissions 867,555 847,435

Win Per Capita $56 $56

Rhythm City Casino/Davenport

Adjusted Gross Revenue $43,913,493 $61,945,577

Admissions 751,346 1,274,293

Win Per Capita $58 $49

Riverside Casino & Golf Course

Adjusted Gross Revenue $85,207,663 $85,682,854

Admissions 1,550,010 1,524,135

Win Per Capita $55 $56

Wild Rose/Clinton

Adjusted Gross Revenue $32,924,975 $31,362,880

Admissions 576,176 567,370

Win Per Capita $57 $55

Wild Rose/Emmetsburg

Adjusted Gross Revenue $29,017,941 $28,420,748

Admissions 450,589 424,122

Win Per Capita $64 $67

Wild Rose/Jefferson

Adjusted Gross Revenue $26,865,904 $28,214,880

Admissions 471,306 442,626

Win Per Capita $57 $64

Totals

Adjusted Gross Revenue $1,437,136,230 $1,452,898,916

Admissions 21,583,433 21,803,401

Win Per Capita $67 $67

Source: Iowa State Racing and Gaming Commission

Read more:

Post-CF project, Hard Rock revenues drop | Local news ... - Sioux City Journal

CRYSTAL FALLS A Crystal Falls teen accused of shooting two horses and an occupied home in Crystal Falls Township earlier this year now faces an attempted murder charge.

Iron County Prosecutor Melissa Powell on Thursday authorized the new charge, a life felony, as well as felony firearm, a two-year felony, against 19-year-old Luke Endjamin Wool.

Powell was unavailable this morning to provide additional information on the development. The amended criminal complaint lists Shawn Colberg as the attempted murder victim.

Previous charges against Wool include discharge a firearm in or at a building, a 10-year felony, and two counts of killing or torturing animals, a four-year felony.

Wools case in Iron County Trial Court has been on hold since April while he undergoes competency and criminal responsibility evaluations.

Wool reportedly told police he shot and killed a draft horse Feb. 24 in Crystal Falls Township while playing American Sniper,' then shot and injured a second horse March 16 because it laughed at him and draft horses are supposed to be in pairs, Powell said in a previous court hearing.

The horses belong to Chuck, Lisa and Jeff Battan.

Iron County deputies went to the March 16 incident after hearing of shots fired at a horse and a nearby occupied home. They were able to connect Wool with the horse found dead Feb. 24 after it broke a leg, severing a main artery.

Wool reportedly told police he listened in on a conversation between his pastor and the pastors wife, who he was living with, to figure out how to get into their gun safe. While the two were out of town, Wool reportedly took five guns and ammunition, according to Powell.

NEGAUNEE Michigan State Police troopers from the Negaunee post are investigating a report of two missing ...

TRAVERSE CITY, Mich. (AP) A two-week search turned up no additional Asian carp in a Chicago waterway where one ...

QUINNESEC Breitung Township will move up scheduled inspection and repairs to the Quinnesec water distribution ...

Read the original:

Attempted murder charge filed against CF teen accused of shooting two horses - Iron Mountain Daily News

Digging Up the Facts on CF Industries Holdings, Inc. (CF) StockNewsJournal CF Industries Holdings, Inc. (CF) is an interesting player in the Basic Materials space, with a focus on Agricultural Chemicals. The stock has been active on the tape, currently trading at $29.72, up from yesterday's close by 6.56%. Given the stock's ...

See the article here:

Digging Up the Facts on CF Industries Holdings, Inc. (CF) - StockNewsJournal

Clinically introduced in 2012, the DynaNail TTC Fusion System is the first and only internal fusion device to harness the pseudoelastic properties of NiTiNOL to offer the compression performance of an external fixator inside an intramedullary (IM) nail design. Compression has shown to be important in not only keeping the bones in close apposition but also in providing the physiological stresses needed to promote bone healing. DynaNail's internal NiTiNOL Compressive Element maintains post-operative compression by automatically adapting for up to 6 mm of bone resorption or settling. During surgery, DynaFrame CF is used to insert DynaNail and stretch the NiTiNOL Compressive Element. Once stretched, DynaFrame CF aids in targeting and placing fixation screws across the DynaNail Implant. The Compressive Element is then activated upon removal of DynaFrame CF.

The DynaFrame CF Deployment System is equipped with several new features from the original DynaNail Targeting Frame. In particular, the carbon fiber PEEK construction provides up to 18X more rigidity than the original PEEK material. Several geometry changes were also implemented including adding more clearance to the distal end of the DynaFrame and its posterior-anterior Targeting Arm to accommodate larger patient anatomies. The increased rigidity from the carbon fiber material along with these additional geometry changes eliminates any issues with drill targeting ensuring a fast, simple procedure every time.

"The release of the DynaFrame CF Deployment System represents an important milestone in DynaNail's commercial progression," said Jeremy Blair, MedShape Vice President of Research and Development. "Based on surgeon feedback, we recognized the need for a deployment system that reduces the number of surgical pearls, more reliably targets the drills, and was versatile for all patient populations. DynaFrame CF addresses these surgical needs with its robust design and carbon fiber material. With these instrumentation updates, the DynaNail TTC Fusion System now pairs intra-operative simplicity and speed with the already unrivaled clinical benefits of the DynaNail implant."

Indicated for use in tibiotalocalcaneal (TTC) fusion surgery, DynaNail has become an effective treatment option to address numerous pathologies, including Charcot neuroarthropathy, severe osteoarthritis, failed total ankle replacement and nonunion from previous arthrodesis procedures. While reported non-union rates with static IM nails are as high as 50%,1 DynaNail has demonstrated clinical success in even high-risk patients with poor healing capacity including diabetics and smokers.2,3

"I am pleased with the new DynaFrame and its ease of use during surgery," said John Kwon MD, Harvard Medical. "I have implanted many DynaNail devices and have been impressed with my patient outcomes to date. DynaNail gives me the confidence that even my most complex patients will receive the compression needed to achieve successful fusion."

For more information on DynaNail, please visit http://www.medshape.com/our-products/dynanail.html.

About MedShape, Inc.: MedShape, Inc. is a privately held medical device company working to develop and commercialize a portfolio of surgical solutions for foot and ankle and trauma surgeons that use its patented advanced material technologies. For more information, visit: http://www.medshape.com.

1Jeng CL, Campbell JT, Tang EY, Cerrato RA, Myerson MS. Tibiotalocalcaneal Arthrodesis with Bulk Femoral Head Allograft for Salvage of Large Defects in the Ankle. Foot and Ankle International, 2013; 34: 1256-1266.

2Latt LD, Dupont KM, Smith KE. Revision Tibiotalocalcaneal Arthrodesis with a Pseudoelastic Intramedullary Nail - A Case Study. Foot and Ankle Specialist, 2017; 10(1): 75-81.

3Hsu AR, Ellington JK, Adams SB, Jr. Tibiotalocalcaneal Arthrodesis Using a NiTiNOL Intramedullary Hindfoot Nail. Foot and Ankle Specialist, 2015; 8(5): 389-96.

DynaNail is a registered trademark of MedShape, Inc.

Media Contact: Jenn Pratt Carabiner Communications 678.313.3438 jpratt@carabinercomms.com

Company Contact: Kathryn Smith, Ph.D. 678.235.3304 Kathryn.smith@medshape.com

View original content:http://www.prnewswire.com/news-releases/medshape-launches-the-dynaframe-cf-deployment-system-for-ttc-fusion-surgery-300486132.html

SOURCE MedShape, Inc.

http://www.medshapesolutions.com

See the original post:

MedShape Launches the DynaFrame CF Deployment System for TTC Fusion Surgery - PR Newswire (press release)

Director of Special Education Leah Reider, left, and Supervisor of Special Education Shannon Brown designed U-CF's U-PRISE Program. (Courtesy image.)

*** Updated 1:59 p.m.***

District Administration, a national publication for school district leaders nationwide, has honored the Unionville-Chadds Ford School District for its U-PRISE program.

The program, which began this past school year, is a place for parents/guardians of students with special needs to share ideas and information, discuss programs, network with other parents and community resources, collaborate with administrators, ask questions, seek advice, and learn more about special education processes. It was the brainchild of Director of Special Education Leah Reider and Supervisor of Special Education Shannon Brown.

Were excited to have this recognition, Brown said. Weve had a lot of support from the administration and parents, but this helps us get the word out more and will allow us to network with other districts.

She called the program a school, family and public partnership and said the families have been appreciative.

U-PRISE serves as a voice for students with disabilities, and their families, in order to promote positive outcomes for students in the district and to provide families with students with disabilities education, resources, and enhanced partnerships with the school district and the community.

"Parent involvement in their child's special education program means a lot to administrators at Unionville-Chadds Ford School District. But participation outside of the Individualized Education Program meetings was limited. When a survey showed parents had an interest in attending a special education support group, the U-PRISE program was created," said District Administration in its recognition of the U-CF program.

U-PRISE hosts an online community bulletin board with resources and information for families. Each district school also has a parent liaison who welcomes new families and acts as a resource for parents navigating the special education system.

To get more information about the program, go to the districts website or contact your students school.

Rich Schwartzman has been reporting on events in the greater Chadds Ford area since September 2001 when he became the founding editor of The Chadds Ford Post. In April 2009 he became managing editor of ChaddsFordLive. He is also an award-winning photographer.

comments

Read more:

National publication recognizes U-CF - Chadds Ford Live

The technicals for CF Industries Holdings, Inc. (CF) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. Hundreds, perhaps thousands of books have been written on trading, strategies, tactics and everything in between. The result has been the mass-proliferation of confusion and less and less attention to the fundamentals of trading success. The fact remains that sound analysis of technical and chart data is still the biggest reason failing traders are transformed into winning traders.

(CF) has shown a marked change in trend levels over the course of recent market activity. Based on recent activity surrounding both the 50 and 200 SMAs, theres been a marked trend created which can be described as bearish. The composite picture painted by the trends built around both SMAs has also created a measured analysis of current investor sentiment as the stock navigates upside and downside risk. The established market sentiment toward the stock has created a trading environment which can suitably be described as negative. There has also been a knock-on effect as it relates to trading volume now reflected in weak real-time sentiment on the buying and selling curve; this has created in turn, indifference toward the stock as measured across a broad statistical mix of the general trading community.

As a composite and comprehensive tableau, the stocks position in the minds of the trading market reflects a broad analysis of technicals and inherent trends which underpin overall market-trading viability.

Relative strength indicator (RSI) and Stochastic measures are two very important leading indicators that help traders gauge overall movement of a particular stock; they act as boosters to technical analysis. Together they show in a measured way, whether or not a stock currently overbought or oversold. This indicator is crucial in determining whether traders are tipped toward the side of buying more of the stock, or doing the opposite and selling more of the stock. This is very important directional information necessary for making trading decisions. (CF)s current measure for its 14-day RSI is 51.83%; this is suggestive that on balance of the indicator, the stock is neutral neither overbought nor oversold and therefore not susceptible to any undue price movements in either direction. The stochastic picture presents a complimentary view of overall sentiment in the present state for (CF). Stochastic data gathered over the last 30 days has created a score of 59.13%. This indicates that the stock is neither overbought or oversold at current levels.

When assessing a trade, it is often necessary to enlist other technical indicators outside of the standard leading set. These, when employed, can often mean the difference between a losing and a winning trade. The omens depict a telling picture in terms of the near-term trading setup for (CF); this makes things very interesting to the curious and interested eye. The +1.12 has created a positive in the trailing 30 days since initiating movement. Over the extended term, the stock has outperformed the S&P 500 by 5.93%. This consistent movement and its attendant overall performance have produced higher daily volatility when compared with other stocks ranking in the same peer group and on the same exchange. The picture looks the same when the stock is assessed against volatility levels measured historically. This historical volatility gives a current reading of 40.14%. These measures of historic volatility are very handy in judging the underlying price momentum and the rate of change in the price of (CF). Bound up this picture of volatility, is another measure that gives the underlying thesis for (CF). This can best be seen by analyzing the readings for the stocks average true range, currently 3.48. ATR is a fine augment to the other indicators outlined above and should be used in conjunction and not as a standalone.

Originally posted here:

20 DMA for CF Industries Holdings, Inc. (CF) moves below 52-week high - NY Stock News